Sanofi (SNY)

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often p...

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, resea...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi i...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchi...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.